NCT04903548 2026-03-24
Evaluating the Effects of Selective Treatment Utilizing Flex-dosing for Unresectable HCC With Y90 SIR-Spheres
Methodist Health System
Completed
Clinical Trials
11 trialsNCT06904196 2025-04-29
Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Recruiting
NCT06707233 2025-01-28
Y-90 SIRT for Unresectable HCC Larger Than 7cm
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Recruiting
NCT06447727 2024-06-07
Efficacy and Safety of 90Y Microsphere Combined With FOLFIRI and Bevacizumab in Second-line Treatment of CRLM
Zhongda Hospital
Recruiting
NCT05992584 2023-09-14
Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Recruiting
NCT05994859 2023-09-14
SIRT for Potentially Resectable HCC
Second Affiliated Hospital of Guangzhou Medical University
Phase NA Recruiting
NCT01126645 2019-05-31
SORAMIC
University of Magdeburg
Phase 2 Completed
NCT01469572 2018-10-18
Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases
Emory University
Phase 1 Completed
NCT01798147 2017-05-23
Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Cholangiocellular Carcinoma (CCC).
Johannes Gutenberg University Mainz
Phase 2 Unknown
NCT01798160 2015-10-20
Selective Internal Radiation Therapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Hepatocellular Carcinoma (HCC).
Johannes Gutenberg University Mainz
Phase 4 Completed
NCT00604409 2015-09-07
Study of Capecitabine in Combination With SIR-Spheres in Patients With Advanced Cancer
Fox Chase Cancer Center
Phase 1 Completed